Compositions of an anticonvulsant and an antipsychotic drug and methods of using the same for affecting weight loss

Abstract

Disclosed are compositions for affecting weight loss comprising a first compound and a second compound, where the first compound is a psychotherapeutic agent and the second compound is a anticonvulsant. Also disclosed are methods of affecting weight loss, increasing energy expenditure, increasing satiety in an individual, or suppressing the appetite of an individual, comprising identifying an individual in need thereof and treating that individual with a psychotherapeutic agent and an anticonvulsant.

1 . A pharmaceutical composition for the prevention of weight gain associated with the use of a psychotherapeutic agent comprising a first compound and a second compound, wherein said first compound is a psychotherapeutic agent and said second compound is an anticonvulsant. 
   
   
       2 . The pharmaceutical composition of  claim 1 , wherein said psychotherapeutic agent is selected from the group consisting of lithium carbonate, lithium citrate, valproate, mixtures thereof, and pharmaceutically acceptable salts or prodrugs thereof. 
   
   
       3 . The pharmaceutical composition of  claim 1 , wherein said anticonvulsant is selected from the group consisting of topiramate, zonisamide, and pharmaceutically acceptable salts or prodrugs thereof, and combinations thereof. 
   
   
       4 . The pharmaceutical composition of  claim 1 , wherein said first compound is a pyschotherapeutic agent and said second compound is a zonisamide. 
   
   
       5 . The pharmaceutical composition of  claim 4 , wherein said first compound is lithium carbonate or lithium citrate. 
   
   
       6 . The pharmaceutical composition of  claim 4 , wherein said first compound is valproate. 
   
   
       7 . The pharmaceutical composition of  claim 1 , wherein said first compound is a salt of lithium and said second compound is zonisamide. 
   
   
       8 . The pharmaceutical composition of  claim 1 , wherein said first compound is valproic acid, or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof, and said second compound is zonisamide. 
   
   
       9 . The pharmaceutical composition of  claim 1 , wherein said first compound is mirtazapine and said second compound is zonisamide. 
   
   
       10 . The pharmaceutical composition of  claim 1 , wherein said first compound is mirtazapine and said second compound is bupropion. 
   
   
       11 . The pharmaceutical composition of  claim 1 , wherein said first compound is setiptiline and said second compound is zonisamide. 
   
   
       12 . The pharmaceutical composition of  claim 1 , wherein said first compound is setiptiline and said second compound is bupropion. 
   
   
       13 . The pharmaceutical composition of  claim 1 , wherein said first compound is mirtazapine and said second compound is a combination of zonisamide and bupropion. 
   
   
       14 . The pharmaceutical composition of  claim 1 , wherein said first compound is setiptiline and said second compound is a combination of zonisamide and bupropion. 
   
   
       15 . A method of preventing weight loss associated with the use of a psychotherapeutic agent, comprising identifying an individual in need thereof and treating that individual with a psychotherapeutic agent and an anticonvulsant. 
   
   
       16 . The method of  claim 15 , wherein the psychotherapeutic agent is selected from the group consisting of lithium carbonate, lithium citrate, and valproate, and pharmaceutically acceptable salts, esters, amides, or prodrugs thereof, and said anticonvulsant is zonisamide. 
   
   
       17 . The method of  claim 15 , wherein the psychotherapeutic agent is selected from the group consisting of mirtazapine, and setiptiline, and pharmaceutically acceptable salts, esters, amides, or prodrugs thereof, and said anticonvulsant is zonisamide. 
   
   
       18 . A method of suppressing the appetite of an individual comprising identifying an individual in need thereof and treating that individual with a first compound and a second compound, wherein said first compound is a psychotherapeutic agent and said second compound is an anticonvulsant. 
   
   
       19 . The method of  claim 18 , wherein the psychotherapeutic agent is selected from the group consisting of lithium carbonate, lithium citrate, and valproate, and pharmaceutically acceptable salts, esters, amides, or prodrugs thereof, and said anticonvulsant is zonisamide. 
   
   
       20 . The method of  claim 18 , wherein the psychotherapeutic agent is selected from the group consisting of mirtazapine, and setiptiline, and pharmaceutically acceptable salts, esters, amides, or prodrugs thereof, and said anticonvulsant is zonisamide.